Quantcast

Latest Biosimilar Stories

2014-10-18 23:00:29

North America is the largest contributor to the global market while Asia is expected to grow at the highest rate. http://www.marketsandmarkets.com/Market-Reports/human-insulin-market-229295783.html (PRWEB) October 19, 2014 The “Human Insulin Market- by Product Type, [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018”...

2014-10-15 16:30:17

Introduces Chairman Gewanter, shows support for BQ proposal GENEVA, Oct. 15, 2014 /PRNewswire/ -- The Alliance for Safe Biologic Medicines (ASBM) presented at the World Health Organization's (WHO) 59(th) International Nonproprietary Naming Stakeholders Session on Tuesday, October 14, 2014. This was the third time ASBM presented to the WHO but the first appearance for ASBM's new chairman Dr. Harry L. Gewanter. As a practicing pediatric rheumatologist and ASBM International Advisory...

2014-10-15 12:32:38

ST. PETERSBURG, Russia, October 15, 2014 /PRNewswire/ -- Russian pharmaceutical companies are actively squeezing out foreign therapeutic manufacturers from the government tenders. The atients' support state program allocates the highest budget for rituximab, a drug used in the treatment of hematological cancers. In 2013, 217 million dollars were appropriated from the federal budget for this drug alone. This year, for the first time, Russian biosimilar drug AcellBia will be...

2014-10-15 12:27:27

A Substantial Need Remains for Emerging SLE Biologics That Can Prevent Acute Flares and That Treat Severe Manifestations, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 15, 2014 /PRNewswire/ -- Decision Resources Group finds that although use of biologics in SLE has increased in the past three years, largely due to uptake of GlaxoSmithKline's Benlysta, overall physician-reported patient share of biologics remains modest. Less than half of SLE patients considered...

2014-10-15 04:22:14

TAINAN, Oct. 15, 2014 /PRNewswire/ -- ScinoPharm (TWSE:1789) announced that it was named the "Active Pharmaceutical Ingredient (API) Supplier of the Year" at the Global Generics and Biosimilars Awards co-hosted by Generics bulletin and Ark Patent Intelligence. The award recognizes excellent performance across a range of business activities and was won in strong competition against a number of leading Pharmaceutical companies including Dr. Reddy's, Teva, Perrigo, Unichem, etc. The...

2014-10-14 08:31:25

DUBLIN, Oct. 14 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Europe Biosimilars Market & Pipeline Insight" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Biosimilars have emerged as one of the most promising segment of the European pharmaceutical industry in recent years. The biosimilars segment has been experiencing a steady growth driven by patent expiration of blockbuster drugs, amenable regulatory framework, economic...

2014-10-10 08:24:12

DUBLIN, Oct. 10, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the...

2014-10-07 12:30:55

CRANBURY, N.J., Oct. 7, 2014 /PRNewswire/ -- Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing complex biosimilars, announced the appointment of Aldeyra Therapeutics CEO Todd C. Brady, M.D., Ph.D, to its Board of Directors. http://photos.prnewswire.com/prnvar/20141006/150533 Pankaj Mohan, Ph.D., Founder and CEO of Oncobiologics, stated, "We are delighted to welcome Dr. Brady to our Board. Given his experience as a venture capital investor,...

2014-10-07 12:28:28

Physicians Indicate that Switching of Currently Treated Patients to Biosimilar Infliximab Is Likely to be Limited, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed rheumatologists in France, Germany and the United States expect to prescribe biosimilar infliximab within one year of launch if the biosimilar is priced at a net discount of 15-30 percent to Remicade and has demonstrated...

2014-10-01 16:27:27

- BIO Investor Forum to be held October 7-8 in San Francisco - SAN DIEGO, Oct. 1, 2014 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today announced that it will be presenting at the 13(th) Annual BIO Investor Forum in San Francisco at the Palace Hotel. Paul Wagner, chief financial officer of Pfenex, will provide an overview of the...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.